Key result
A fixed-dose combination of amlodipine, atorvastatin, and perindopril (Lipertans) can improve treatment adherence and control both blood pressure and lipid levels in patients with comorbid hypertension and dyslipidemia.
Why the study?
Hypertension and dyslipidemia frequently coexist as key cardiovascular risk factors, but patient adherence to lipid-lowering therapy remains low in primary prevention.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Fixed-dose combinations of antihypertensive and lipid-lowering drugs, such as amlodipine/perindopril/atorvastatin, may improve patient adherence and risk factor control in primary prevention.
The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can significantly increase the effectiveness of therapy.
No takes yet. Share an insight, caveat, or question.
В. В. Кашталап (2022) conducted a case report in Hypertension and dyslipidemia (n=1). Lipertans (amlodipine, atorvastatin, perindopril) was evaluated. A fixed-dose combination of amlodipine, atorvastatin, and perindopril (Lipertans) can improve treatment adherence and control both blood pressure and lipid levels in patients with comorbid hypertension and dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: